April 2023
Discussing AxSpA: AS Associated MACE & Upadacitinib's Long Term Safety
Join Dr. Sofia Ramiro and Professor Hideto Kameda as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. The first of our publications discusses the incidence of MACEs in French patients newly benefiting from the French Long-term Illness scheme (LTI) for AS and to evaluate the effect of various treatments on the risk of MACE occurrence. Our second paper the goes on to evaluate the long-term safety profile for upadacitinib across RA, PsA, AS and AD.
Discussing Rheumatology: April 2023
Join Prof Iain McInnes as he reviews two interesting papers that help to broaden our understanding and knowledge on the safety of biologic and targeted synthetic DMARDs. In the first of today’s papers, Matthew Baker and colleagues determine the risk of developing interstitial lung disease (ILD) in patients with RA, undergoing treatment with different biologic and targeted synthetic DMARDs. In the second paper, Lars Kristensen and team analyse data from ORAL Surveillance to help identify subpopulations with different relative risk (i.e., ’high-risk’ and ’low-risk’) with tofacitinib versus TNFi.
March 2023
Discussing PsA: Herpes Zoster in JAK Inhibitor Therapies & The APEX Protocol
Join Professors Iain McInnes, Laura Coates, and Peter Nash as they discuss the latest top research in PsA. The first paper we will discuss aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with either TOFA, BARI or UPA. The second paper then goes on to describe the methodology being undertaken in the ground-breaking Phase 3b APEX study, which seeks to further assess the effects of guselkumab Q4W and Q8W on PsA outcomes.
Discussing Rheumatology: March 2023
Join Prof Iain McInnes as he reviews two interesting papers. In the first of today’s papers, Jeffrey Curtis and colleagues aimed to evaluate malignancies and their associations with baseline risk factors and CV risk scores with tofacitinib vs TNFi in a CV risk-enriched RA population from the ORAL Surveillance study. In the second paper today, Peter Taylor and his team analyse data from the baricitinib clinical trial programme for rheumatoid arthritis, atopic dermatitis, and alopecia areata, to help further characterise adverse events of special interest for JAK inhibitors in ‘at-risk’ populations.
Author Interview: Charis Meng
Dr. Charis Meng, a rheumatologist at the Hospital for Special Surgery and Assistant Professor at Weill Cornell Medical College in New York. In this edition, Dr Meng discusses her latest paper ‘Can Patients with Controlled Rheumatoid Arthritis Taper Methotrexate from Targeted Therapy and Sustain Remission? A Systematic Review and Meta-analysis.’
February 2023
Discussing Rheumatology: February 2023
Join Prof Iain McInnes as he reviews two interesting papers. In the first paper, Professor Maxime Dougados and colleagues shed some more light into the findings from the ORAL Surveillance trial, in comparison to those seen in the tofacitinib clinical development programme. And, in the second paper, Professor Kevin Winthrop and colleagues continue to report on safety by providing us with the latest findings from their review into opportunistic infections associated with JAK inhibitor treatment for RA.